GPCR Structure Therapeutics Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$49.35

Period return

-42.52 (-46.28%)

Volume

297.0K

2026-07-21O $46.91 H $49.42 L $46.06 C $49.35MA5 $48.09MA20 $51.01MA60 $43.98MA120 $52.44

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.01%
2026. 04. 27.MediumBUY3 months ago
Canaccord Genuity: Buy
US analyst rating / recommendation change.
2026. 03. 17.LowBUY4 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 02.LowBUY5 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 02. 27.LowBUY5 months ago
Citizens: Market Outperform
US analyst rating / recommendation change.
2026. 01. 23.LowBUY6 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 01. 20.LowBUY6 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2025. 12. 20.LowBUY7 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 12. 13.LowBUY7 months ago
Morgan Stanley: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $106.47 · 16 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Sector: Healthcare
Industry

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	181,415	$8.74M	0.01%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	95,543	$6.65M	0.01%	—	New position

Structure Therapeutics Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 04. 27.	Canaccord Genuity	—	Initiate coverage	— → Buy	—	Canaccord Genuity: Buy
2026. 03. 17.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 03. 02.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 02. 27.	Citizens	—	Maintain	Market Outperform → Market Outperform	—	Citizens: Market Outperform
2026. 01. 23.	JP Morgan	—	Maintain	Overweight → Overweight	—	JP Morgan: Overweight
2026. 01. 20.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy